Delving into the Latest Updates on Tofacitinib Citrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Rhofanib, Tasocitinib, Tasocitinib citrate

+ [26]

Target

JAK1 x JAK2 x JAK3

Action

inhibitors

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [5]

Active Indication

Oligoarticular ArthritisPolyarticular Juvenile Idiopathic ArthritisAnkylosing Spondylitis+ [13]

Inactive Indication

Allograft RejectionChronic large plaque psoriasisCOVID-19+ [18]

Originator Organization

Pfizer Inc.

Active Organization

TWi Biotechnology, Inc.Pfizer Europe MA EEIG

Pfizer Inc.

+ [15]

Inactive Organization

Pfizer Manufacturing Deutschland GmbH

License Organization

Takeda Pharmaceutical Co., Ltd.

Pfizer Inc.

Maijin Biomedical Technology (Shanghai) Co., Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (06 Nov 2012),

Rheumatoid Arthritis

RegulationSpecial Review Project (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H28N6O8

InChIKeySYIKUFDOYJFGBQ-YLAFAASESA-N

CAS Registry540737-29-9

This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.

Start Date01 Jun 2026

Sponsor / Collaborator-

NCT07313072

/ Not yet recruitingPhase 2IIT

Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

To evaluate the efficacy and safety of topical 2% tofacitinib nail lacquer in nail psoriasis, using the NAPSI and DLQI scales before and after 26 weeks of treatment.

Start Date01 Mar 2026

Sponsor / Collaborator-

CTRI/2025/12/098992

/ Not yet recruitingNot ApplicableIIT

STRIDE-AS-Strategic tofacitinib dose reduction in axial spondyloarthritis:A multicentre randomized controlled assessor blinded,non inferiority trial - STRIDE-AS

Start Date20 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Tofacitinib Citrate

Login to view more data

100 Translational Medicine associated with Tofacitinib Citrate

Login to view more data

100 Patents (Medical) associated with Tofacitinib Citrate

Login to view more data

4,541

Literatures (Medical) associated with Tofacitinib Citrate

31 Dec 2026·ANNALS OF MEDICINE

Efficacy of Janus kinase inhibitor combined with phototherapy in non-segmental vitiligo: systematic review and meta-analysis

Review

Author: Mubeen, Manahil ; D. Rai, Kuldeep ; Ishtiaq, Jawad ; Poudel, Sijan ; Saeed, Anzel ; K. Sangtiani, Aneesh ; Shuaib, Laiba

BACKGROUND:

Vitiligo is a chronic autoimmune disease causing skin depigmentation and psychosocial issues. Non-segmental vitiligo often shows limited response to standard therapies. The IFN-γ-JAK-STAT pathway plays a key role, and combining JAK inhibitors with NB-UVB may improve repigmentation.

AIM:

To evaluate the efficacy of JAK inhibitors (baricitinib or tofacitinib) plus NB-UVB versus NB-UVB without JAK inhibitors in adult NSV.

METHODS:

PubMed, Cochrane, and ClinicalTrials.gov were searched till August 2024 for randomized controlled trials. Four studies, comprising 217 adults (121 in the combination group and 96 in the control group), were analyzed using RevMan 5.4. Bias was assessed via Newcastle-Ottawa, Cochrane ROB-2, and ROBINS-I tools.

RESULTS:

Combination therapy significantly reduced total VASI compared to controls (MD = -4.96, 95% CI [-9.29, -0.63], p = 0.02), with a greater effect on sensitivity analysis (MD = -6.84, p = 0.0007). Significant reductions were seen in face/neck (MD = -0.17, p = 0.002), trunk (MD = -3.62, p = 0.0001); acral (MD = -0.85, p = 0.0002) and extremity (MD = -4.61, p < 0.00001) regions after sensitivity analysis. Patients were more likely to achieve ≥50% (RR = 6.87, p < 0.00001) and ≥75% (RR = 15.13, p = 0.006) repigmentation.

CONCLUSIONS:

JAK inhibitor plus NB-UVB markedly improves the repigmentation in adult NSV compared to NB-UVB alone.

01 Apr 2026·JOURNAL OF ETHNOPHARMACOLOGY

Understanding senna risks: Evidence from the FDA adverse event reporting system

Article

Author: Liu, Wei ; Zhao, Jingyi ; Chen, Yan ; Ma, Shuai ; Zhang, Wenhui ; Chen, Jingwen ; Du, Chao ; Yao, Yinhui

ETHNOPHARMACOLOGICAL RELEVANCE:

Senna, a medicinal plant widely utilized across the globe and classified within the leguminous family, is traditionally characterized by its sweet, bitter, and cold properties and is associated with the large intestine meridian in various traditional medicine systems. It is renowned for its therapeutic properties, including its abilities to purge heat, alleviate stagnation, relax the bowels, and induce diuresis. Despite its prevalent use for its laxative effects, the safety profile and potential adverse events (AEs) associated with senna remain inadequately explored, particularly within the realm of pharmacovigilance.

AIM OF THE STUDY:

This study seeks to analyze the adverse events associated with senna as reported in the FDA Adverse Event Reporting System (FAERS) from 2004 to 2024. It aims to evaluate the strength of the signals for these adverse events and to identify potential risk factors.

MATERIALS AND METHODS:

Data were sourced from the FAERS database, comprising 21,890,177 reports related to senna. Following the removal of duplicate entries, a total of 18,282,801 reports were subjected to analysis for adverse events (AEs), categorized according to the System Organ Class (SOC) and Preferred Term (PT) levels. Disproportionality analyses were conducted utilizing algorithms including the reporting odds ratio (ROR), proportionate reporting ratio (PRR), information component (IC), and empirical Bayes geometric mean (EBGM). To identify significant risk factors, time-to-onset (TTO) analysis and logistic regression were applied. Furthermore, the modified Bradford Hill criteria were employed to assess global causal relationships, examining elements such as the strength of association, analogy, consistency, biological plausibility, and temporality to determine potential causal links between senna use and AEs.

RESULTS:

The study identified a significant increase in reported AEs over the study period, with the highest incidence observed in 2024 (n = 423). Immune system disorders were the most frequently reported system organ class (SOC) (n = 1722), followed by gastrointestinal disorders and hypersensitivity reactions. Females constituted 62.86 % of the reported AEs, while individuals aged over 60 years accounted for 32.09 % of cases. The majority of AEs occurred within the first week of treatment, with a median onset time of 4 days. Logistic regression analysis identified several independent risk factors for immune system disorders, including advanced age, female sex, and the use of concomitant medications such as ascorbic acid and tofacitinib citrate. The global assessment indicated that multiple Bradford Hill criteria were satisfied, suggesting a plausible causal relationship.

CONCLUSIONS:

The findings suggest a potential link between senna use and immune system disorders, highlighting the need for careful monitoring of its safety profile in clinical practice. Further research is necessary to elucidate the mechanisms underlying these adverse reactions.

01 Mar 2026·JOINT BONE SPINE

Impact of drug-drug interaction of JAK inhibitors, CYP enzyme inhibitors and OAT3 inhibitors on persistence and infection rates in patients with autoimmune rheumatic diseases

Article

Author: Chen, Yen-Ju ; Kao, Chung-Mao ; Shao, Yu-Hsuan Joni ; Chen, Yi-Ming ; Liao, Yi-Ju ; Chen, I-Chieh ; Chen, Yi-Ting ; Kuo, Tzu-Tung

OBJECTIVES:

Janus kinase (JAK) inhibitors are effective treatments for autoimmune rheumatic diseases (AIRDs). However, concomitant use of JAK inhibitors with CYP enzyme inhibitors or OAT3 inhibitors can lead to drug-drug interactions. This study aimed to evaluate the impact of the concomitant use of CYP and OAT3 inhibitors on discontinuation of treatment and infectious complications in patients treated with JAK inhibitors.

METHODS:

Using the National Health Insurance Research Database, this retrospective cohort study included patients with rheumatoid arthritis, psoriatic arthritis and atopic dermatitis treated with JAK inhibitors in 2021-2023. The risks of discontinuation of treatment and infectious complications were evaluated using Cox proportional hazards models, adjusted for age, gender, other infectious and concomitant use of steroids or methotrexate.

RESULTS:

Among 7591 patients, concomitant use of strong CYP3A4, or CYP2C19 inhibitors increased the risk of treatment discontinuation for tofacitinib and baricitinib from 41% to 144%. The risk of overall infectious complications also increased when tofacitinib was used concomitantly with strong CYP2C19 inhibitors. The risk of pneumonia was further increased by concomitant use of strong CYP2C19 inhibitors with all JAK inhibitors and CYP3A4 inhibitors with tofacitinib. The risk of urinary tract infection was increased by concomitant use of strong CYP2C19 inhibitors when used with tofacitinib, or baricitinib.

CONCLUSIONS:

Concomitant use of strong CYP3A4, and CYP2C19 inhibitors with JAK inhibitors significantly increases the risk of discontinuation of treatment and infectious complications in patients with AIRDs. Careful consideration of drug-drug interactions is necessary when prescribing JAK inhibitors to optimize treatment persistence and minimize adverse events.

333

News (Medical) associated with Tofacitinib Citrate

03 Feb 2026

·www.pharmaceutical-technology.com

Pfizer sets sights on R&D strategy amid modest FY25 results

Pfizer and investors alike look forward to further developments within the pharma’s newly acquired obesity portfolio. Image credit: ShU studio via ShutterStock.com. New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company looks to refresh its portfolio amid looming patent losses and waning Covid vaccine sales. In FY25, Pfizer generated full-year revenues of $62.6bn. While this meets the company’s previously adjusted FY25 profit forecast of $62bn , it represents a 2% operational decline compared to FY24. Earnings per share (EPS) were in line with Citi analyst consensus, standing at $1.36, although they were lower than the 2024 rate of $1.41. The company also reaffirmed its 2026 financial guidance, with revenues between $59.5bn and $62.5bn expected, with a diluted EPS range of $2.80 to $3.00. The results follow a tough 2025 for Pfizer, in which the company has battled with declining Covid-19 vaccine sales and the upcoming loss of exclusivity impacting several key drugs in its portfolio, including Janus kinase (JAK) inhibitor, Xeljanz (tofacitinib). Currently, Pfizer forecasts that patent expiries will result in $1.5bn of revenue losses in FY26. Despite this overall loss, 2025 revenues were looking more favourable when Covid-19 vaccines Paxlovid (nirmatrelvir/ritonavir) and Comirnaty (Covid-19 vaccine, mRNA) were discounted from the equation – with the rest of the company’s pipeline achieving operational growth of 6%. Within its wider primary care portfolio, Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo was a strong driver of growth, bringing in $1bn across the global market – up 37% from the $755m in total sales achieved in FY24. This offset the 9% total revenue decline observed in the US, which comes amid the Trump administration’s continued efforts to alter vaccine policy . Sanofi’s RSV jab, Beyfortus (nirsevimab), experienced a similar, but steeper decline in US sales during FY2025 . GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Pfizer and Bristol Myers Squibb’s (BMS) best-selling blood thinner, Eliquis (apixaban), also had a good year, posting an 8% sales increase compared to 2024, with $7.96bn in total sales for 2025. However, this may be one of the last years of consistent growth for the factor Xa blocker, as its key patents are set to expire between 2027 and 2029. Within its oncology portfolio, Pfizer touted positive financial results from its antibody-drug conjugate (ADC) Padcev (enfortumab vedotin), which made 22% more than 2024 by generating global sales of $1.94bn. It was a similar story for anaplastic lymphoma kinase (ALK) inhibitor Lorbrena (lorlatinib), which hit blockbuster status while demonstrating YoY growth of 40%. Despite these wins, investors do not appear to be best pleased with Pfizer’s overall FY25 sales outcome, as the pharma’s stock value dropped by 4.9% from $26.66 at market close on 2 February to $25.36 at market open on 3 February after the results debuted. The New York-based pharma has a market cap of $144.4bn. Pfizer focuses on R&D to foster future growth In an investor call held on 3 February, Pfizer’s CEO, Albert Bourla, touted 2026 as a “key catalyst” for the company’s future growth up to 2030, noting that the initiation of 20 key pivotal studies will help “maximise opportunities” for the company. At the recent 2026 J.P. Morgan Healthcare Conference in San Francisco, Bourla shared Pfizer’s plans to deliver a “catalyst-rich R&D agenda,” while maximising the value of its recent transactions – including its $10bn buyout of obesity biotech, Metsera . This deal already appears to be reaping benefits for Pfizer, as its newly acquired, once-monthly glucagon-like peptide 1 receptor agonist (GLP-1RA), PF3994, met its primary trial endpoint of significant weight reduction at 28 weeks during the Phase IIb VESPER-3 study (NCT06973720). The therapy, which was previously known as MET-097i, is now expected to enter 10 Phase III trials in 2026 across the obesity space. In a research note, Citi analysts noted that they were most compelled by the successful transition to a monthly dosing schedule, as well as the continued weight loss trajectory with no observed plateau, which they say could “reinforce confidence in the asset’s potential”. To help fund studies on its clinical pipeline, Bourla noted that Pfizer has been, and will continue to create cost savings within R&D and across the wider business through the deployment of artificial intelligence (AI). Adding to Bourla’s point, Chris Boshoff, CSO and president of R&D, says the company is “recruiting and embedding AI engineers” across discovery, medical regulatory, safety, pharmacovigilance and clinical trial execution to “measure success, productivity, speed and costs”.

Clinical ResultPhase 2VaccineAcquisitionPhase 1

29 Jan 2026

·www.drugs.com

Medicare to Negotiate Lower Prices for Botox and 14 Other Major Drugs

THURSDAY, Jan. 29, 2026 — Fifteen prescription medications, including Botox and the diabetes drug Trulicity , will be the focus of federal price negotiations that could lower prices for Medicare patients. An outgrowth of the U.S. Inflation Reduction Act of 2022 , the talks aim to lower costs for some of the most expensive treatments used by seniors. Results of the first round of negotiations with drug makers went into effect this year. The medications chosen for this negotiation cycle represent roughly $27 billion in total prescription drug spending under Medicare Part B and Part D, according to the Centers for Medicare and Medicaid Services (CMS). Part B covers drugs like intravenous chemotherapy that are administered in a medical facility; Part D covers prescription drugs. Prices negotiated in the new round of talks will go into effect in 2028. Manufacturers have until Feb. 28 to decide if they will participate. While companies can opt out, doing so would likely result in their drug being removed from Medicare's covered drugs list — one of the nation’s largest markets. To date, no drugmaker has walked away from the program during previous negotiation rounds, according to NBC News . The list covers the top 15 highest spending drugs for Medicare across a variety of serious health conditions. The medications up for negotiation this year include: Cancer drugs: Erleada (prostate cancer); Kisqali (breast cancer); Verzenio (breast cancer); and Lenvima (several cancers) Autoimmune treatments: Cimzia (Crohn's disease); Cosentyx (psoriasis); Entyvio (Crohn's disease and ulcerative colitis); Orencia (rheumatoid arthritis); and Xeljanz and Xeljanz XR (autoimmune conditions) Chronic conditions: Anoro Ellipta (COPD); Biktarvy (HIV); Trulicity (type 2 diabetes); Rexulti (major depressive disorder, schizophrenia, or agitation associated with dementia due to Alzheimer’s disease); and Xolair (asthma and allergies) Botox is included for its medical applications rather than cosmetic ones. Medicare covers the drug for conditions such as chronic migraines, overactive bladder and muscle spasms. The Trump administration also plans to renegotiate the price for the diabetes medication Tradjenta , which was part of a previous round of talks. This follows a recent announcement of lower costs for Ozempic and Wegovy , which are scheduled to go into effect in 2027, according to NBC News . Sources NBC News, Jan. 27, 2025

28 Jan 2026

·endpoints.news

Round three of IRA negotiations is expected to be ‘manageable’ for pharma

Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS unveiled the next 15 drugs up for negotiation, which include AbbVie’s Botox, Eli Lilly’s diabetes drug Trulicity, and Gilead’s HIV treatment Biktarvy. Analysts said some of the drugs were widely anticipated to make the list. They cited past negotiations, upcoming patent losses and new drug development as some reasons why the potential impacts may be modest. “With prior rounds of pricing negotiations reasonable, and several of these medicines set to lose exclusivity in the near-term, we continue to expect that the impacts will be manageable,” BMO Capital Markets analyst Evan Seigerman said in a note to investors. He called out Biktarvy, Botox, Trulicity, Eisai’s Lenvima, Bristol Myers Squibb’s Orencia, Lilly’s Verzenio and Pfizer’s Xeljanz specifically, as they fall under BMO’s coverage. CMS said the 15 new drugs on the list cost Medicare Part B and Part D about $27 billion from November 2024 through October 2025. But Leerink analysts suggested in a note that Biktarvy is “the only one of the 15 drugs that has [estimated] Medicare exposure that is material.” Even so, Leerink analyst Daina Graybosch told Endpoints News in an interview that the impact on Gilead’s revenue is likely “modest.” “Investors are thinking more about the growth beyond Biktarvy anyways,” she said, citing the company’s “really rich HIV pipeline.” Gilead launched its twice-yearly drug for HIV prevention Yeztugo last year, and said earlier this month that it hopes to have up to seven HIV prevention and treatment launches by the end of 2033. A Gilead spokesperson said on Wednesday that the company plans to participate in negotiations, and is “committed to demonstrating the value and innovation of our medicines while supporting patient access and affordability.” Some drugmakers continue to attack the program. Novartis called the program unconstitutional in a statement to Endpoints on Tuesday, and Bristol Myers said “the IRA’s forced sale regime is deeply flawed.” The BMS spokesperson added that the program “creates negative, long-term implications on patient access, R&D and future innovation.” Novartis and BMS are two of six drugmakers that have asked the Supreme Court to review challenges they brought against the first round of Medicare negotiations. PhRMA EVP of policy and research Elizabeth Carpenter said the law is “the wrong approach for Americans,” and is “undermining future medical progress.” Some drugmakers suggested in early statements they would cooperate with CMS. UCB said it is “prepared to work collaboratively” with the agency in discussions for its drug Cimzia. Takeda said it anticipated the inclusion of its drug Entyvio for Crohn’s disease and ulcerative colitis, and has been “actively preparing” for possible negotiations. A spokesperson said the company is “focused on supporting continued access to Entyvio for patients who may benefit from this critical medicine.” Otsuka, which markets the antipsychotic medicine Rexulti with Lundbeck, told Endpoints that it “remains committed to ensuring patients have access to safe and effective treatments for serious mental illnesses and neurological conditions.” Lundbeck noted that Rexulti’s patent expiration is in mid-2029, and that “approximately 35% of US Rexulti revenue is exposed to Medicare.”

100 Deals associated with Tofacitinib Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09783	Tofacitinib Citrate	L04AA29	DB08895

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Oligoarticular Arthritis	European Union	Pfizer Europe MA EEIG	22 Mar 2017
Oligoarticular Arthritis	Iceland	Pfizer Europe MA EEIG	22 Mar 2017
Oligoarticular Arthritis	Liechtenstein	Pfizer Europe MA EEIG	22 Mar 2017
Oligoarticular Arthritis	Norway	Pfizer Europe MA EEIG	22 Mar 2017
Polyarticular Juvenile Idiopathic Arthritis	European Union	Pfizer Europe MA EEIG	22 Mar 2017
Polyarticular Juvenile Idiopathic Arthritis	Iceland	Pfizer Europe MA EEIG	22 Mar 2017
Polyarticular Juvenile Idiopathic Arthritis	Liechtenstein	Pfizer Europe MA EEIG	22 Mar 2017
Polyarticular Juvenile Idiopathic Arthritis	Norway	Pfizer Europe MA EEIG	22 Mar 2017
Ankylosing Spondylitis	Australia	Pfizer Australia Pty Ltd.	05 Feb 2015
Arthritis, Psoriatic	Australia	Pfizer Australia Pty Ltd.	05 Feb 2015
Colitis, Ulcerative	Australia	Pfizer Australia Pty Ltd.	05 Feb 2015
Juvenile Idiopathic Arthritis	Australia	Pfizer Australia Pty Ltd.	05 Feb 2015
Rheumatoid Arthritis	United States	PF Prism CV	06 Nov 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	NDA/BLA	China	Pfizer Manufacturing Deutschland GmbH	06 Jan 2022
Glioblastoma Multiforme	Phase 3	United States	Pfizer Inc.	07 Oct 2022
COVID-19	Phase 3	Brazil	Pfizer Inc.	16 Sep 2020
Systemic onset juvenile chronic arthritis	Phase 3	United States	Huizhi Pharmaceutical (Dalian) Co., Ltd.	10 May 2018
Systemic onset juvenile chronic arthritis	Phase 3	United States	Pfizer Inc.	10 May 2018
Systemic onset juvenile chronic arthritis	Phase 3	United States	Pharmacia & Upjohn	10 May 2018
Systemic onset juvenile chronic arthritis	Phase 3	China	Pfizer Inc.	10 May 2018
Systemic onset juvenile chronic arthritis	Phase 3	Argentina	Pharmacia & Upjohn	10 May 2018
Systemic onset juvenile chronic arthritis	Phase 3	Argentina	Huizhi Pharmaceutical (Dalian) Co., Ltd.	10 May 2018
Systemic onset juvenile chronic arthritis	Phase 3	Argentina	Pfizer Inc.	10 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04496960 (CTgov)	Phase 1/2	Primary Sjögren's syndrome	23	Tofacitinib (Drug: Tofacitinib)	mpxgrqgeay = zyzdtvpsms givxbufleu (pbuolkzent, ypywgpiuia - ibuumknlad) View more	-	18 Dec 2025
				Placebo (Placebo)	mpxgrqgeay = wwuotfxqvj givxbufleu (pbuolkzent, bdbfusapfl - rwtewqgeun) View more
NCT04246372 (CTgov)	Phase 2	Alopecia Areata \| Psoriasis \| Vitiligo ... View more	47	Tofacitinib	kzxrbfbaeo = aowqqnsszx gzhyypwdgv (pdjigaygjp, vvbxtkdqjl - ghrmzhqdvw) View more	-	11 Dec 2025
NCT01877668 (Pubmed \| Rheumatol Ther)	Phase 3	Arthritis, Psoriatic	323	Tofacitinib	hntuidkwjz(kmzeowedmk) = pjbhmxanhh frbjxyrtku (pokjmnakxz ) View more	Positive	28 Oct 2025
				Placebo	hntuidkwjz(kmzeowedmk) = kahutlidjv frbjxyrtku (pokjmnakxz ) View more
ACR2025 Manual	Not Applicable	Rheumatoid Arthritis	12,552	Tofacitinib	otxftqlrlm(pzntsrshuh): RR = 1.694 (95.0% CI, 1.29 - 2.24), P-Value = <0.0001 View more	Negative	24 Oct 2025
				Upadacitinib
ACR2025	Not Applicable	Rheumatoid Arthritis	21,340	Tofacitinib	hsxulbppwl(qhiwdoemte) = cbwfbpskuo artuxpnlht (lpohizivfs ) View more	Positive	24 Oct 2025
				TNFi	hsxulbppwl(qhiwdoemte) = wzjrolhmby artuxpnlht (lpohizivfs ) View more
ACR2025	Not Applicable	Juvenile Idiopathic Arthritis	23	Tofacitinib	uahjmiguzr(nzwcimpkvh) = No adverse event were recorded. bdzfxavqoi (sdbjvlxlzz ) View more	Positive	24 Oct 2025
ACR2025	Not Applicable	Axial Spondyloarthritis	290	Tofacitinib	ysbhkqaibj(sgbdantmjo) = xuotjnjjmp rxnnqycisu (azpcfkcqmu ) View more	Positive	24 Oct 2025
ACR2025	Not Applicable	Arthritis	10	Tofacitinib and TNF inhibitors	oqwspvbgup(qopcubahja) = tskzpvlujw ljaqxjmkkm (lfmldgxadt )	Positive	24 Oct 2025
ACR2025	Not Applicable	Juvenile-Onset Scleroderma	7	Tocilizumab	qomhcnxcza(tlbfkbewrx) = jpkcpqnzgp cicvqazaxp (mvfzexoslj ) View more	Positive	24 Oct 2025
				Tofacitinib	qomhcnxcza(tlbfkbewrx) = puvaowbqhj cicvqazaxp (mvfzexoslj ) View more
ACR2025	Not Applicable	Immunoglobulin G4-Related Disease	58	Tofacitinib plus Glucocorticoids	cqxiberowg(tyeyizbuzq) = Four infections occurred in the combination group, (two urinary tract infection, one herpes zoster and one pulmonary infection), but the overall incidence of adverse events did not differ significantly between the groups (p = 0.311). No serious adverse events occurred. kkrxnetinp (wubounhpds ) View more	Positive	24 Oct 2025
				Glucocorticoids